company background image
RVU

Ryvu Therapeutics WSE:RVU Stock Report

Last Price

zł33.30

Market Cap

zł611.2m

7D

5.7%

1Y

-43.1%

Updated

03 Oct, 2022

Data

Company Financials +
RVU fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

RVU Stock Overview

Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology.

Ryvu Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ryvu Therapeutics
Historical stock prices
Current Share Pricezł33.30
52 Week Highzł66.00
52 Week Lowzł22.20
Beta0.44
1 Month Change1.68%
3 Month Change30.59%
1 Year Change-43.08%
3 Year Change-45.59%
5 Year Change-26.20%
Change since IPO516.67%

Recent News & Updates

Shareholder Returns

RVUPL Life SciencesPL Market
7D5.7%3.5%-4.7%
1Y-43.1%-36.8%-36.0%

Return vs Industry: RVU underperformed the Polish Life Sciences industry which returned -36.8% over the past year.

Return vs Market: RVU underperformed the Polish Market which returned -36% over the past year.

Price Volatility

Is RVU's price volatile compared to industry and market?
RVU volatility
RVU Average Weekly Movement13.9%
Life Sciences Industry Average Movement7.1%
Market Average Movement6.1%
10% most volatile stocks in PL Market11.6%
10% least volatile stocks in PL Market3.9%

Stable Share Price: RVU is more volatile than 90% of Polish stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: RVU's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Polish stocks.

About the Company

FoundedEmployeesCEOWebsite
2007195Pawel Przewiezlikowskihttps://www.ryvu.com

Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company’s products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia.

Ryvu Therapeutics Fundamentals Summary

How do Ryvu Therapeutics's earnings and revenue compare to its market cap?
RVU fundamental statistics
Market Capzł611.24m
Earnings (TTM)-zł90.51m
Revenue (TTM)zł37.51m

16.3x

P/S Ratio

-6.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RVU income statement (TTM)
Revenuezł37.51m
Cost of Revenuezł13.23m
Gross Profitzł24.28m
Other Expenseszł114.78m
Earnings-zł90.51m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Nov 23, 2022

Earnings per share (EPS)-4.93
Gross Margin64.72%
Net Profit Margin-241.30%
Debt/Equity Ratio0.9%

How did RVU perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is RVU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RVU?

Other financial metrics that can be useful for relative valuation.

RVU key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue14.7x
Enterprise Value/EBITDA-7.1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does RVU's PS Ratio compare to its peers?

RVU PS Ratio vs Peers
The above table shows the PS ratio for RVU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average14.7x
SLV Selvita
4.2x22.1%zł1.6b
NNG NanoGroup
45.7xn/azł21.5m
BML BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek
8.9xn/azł390.9m
BIO BIOTON
1.7xn/azł312.5m
RVU Ryvu Therapeutics
17.1x-6.8%zł641.5m

Price-To-Sales vs Peers: RVU is expensive based on its Price-To-Sales Ratio (17.1x) compared to the peer average (14.7x).


Price to Earnings Ratio vs Industry

How does RVU's PE Ratio compare vs other companies in the European Life Sciences Industry?

Price-To-Sales vs Industry: RVU is expensive based on its Price-To-Sales Ratio (17.1x) compared to the European Life Sciences industry average (4.4x)


Price to Sales Ratio vs Fair Ratio

What is RVU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RVU PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio16.3x
Fair PS Ratio7.8x

Price-To-Sales vs Fair Ratio: RVU is expensive based on its Price-To-Sales Ratio (17.1x) compared to the estimated Fair Price-To-Sales Ratio (7.9x).


Share Price vs Fair Value

What is the Fair Price of RVU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RVU's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RVU's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Future Growth

How is Ryvu Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


4.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RVU is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RVU is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RVU is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RVU's revenue is expected to decline over the next 3 years (-6.8% per year).

High Growth Revenue: RVU's revenue is forecast to decline over the next 3 years (-6.8% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RVU's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Ryvu Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-53.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: RVU is currently unprofitable.

Growing Profit Margin: RVU is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RVU is unprofitable, and losses have increased over the past 5 years at a rate of 53.3% per year.

Accelerating Growth: Unable to compare RVU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RVU is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (16.3%).


Return on Equity

High ROE: RVU has a negative Return on Equity (-59.93%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Ryvu Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: RVU's short term assets (PLN79.1M) exceed its short term liabilities (PLN24.4M).

Long Term Liabilities: RVU's short term assets (PLN79.1M) exceed its long term liabilities (PLN26.0M).


Debt to Equity History and Analysis

Debt Level: RVU has more cash than its total debt.

Reducing Debt: RVU's debt to equity ratio has reduced from 8.9% to 0.9% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RVU has sufficient cash runway for 10 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: RVU is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies

Dividend

What is Ryvu Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Ryvu Therapeutics Dividend Yield vs Market
How does Ryvu Therapeutics dividend yield compare to the market?
SegmentDividend Yield
Company (Ryvu Therapeutics)n/a
Market Bottom 25% (PL)3.1%
Market Top 25% (PL)9.5%
Industry Average (Life Sciences)0.7%
Analyst forecast in 3 Years (Ryvu Therapeutics)n/a

Notable Dividend: Unable to evaluate RVU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RVU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RVU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RVU's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as RVU has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.7yrs

Average management tenure


CEO

Pawel Przewiezlikowski

no data

Tenure

zł524,126

Compensation

Mr. Pawel Tadeusz Przewiezlikowski, MSc., MBA, serves as the Chief Executive Officer of BioCentrum Sp. z o.o. Mr. Przewiezlikowski serves as a Member of Supervisory Board of SELVITA S.A.Mr. Przewiezlikow...


CEO Compensation Analysis

Pawel Przewiezlikowski's Compensation vs Ryvu Therapeutics Earnings
How has Pawel Przewiezlikowski's remuneration changed compared to Ryvu Therapeutics's earnings?
DateTotal Comp.SalaryCompany Earnings
Mar 31 2022n/an/a

-zł91m

Dec 31 2021n/an/a

-zł78m

Sep 30 2021n/an/a

-zł72m

Jun 30 2021n/an/a

-zł61m

Mar 31 2021n/an/a

-zł41m

Dec 31 2020n/an/a

-zł32m

Sep 30 2020n/an/a

-zł40m

Jun 30 2020n/an/a

-zł32m

Mar 31 2020n/an/a

-zł41m

Dec 31 2019zł524kzł524k

-zł44m

Sep 30 2019n/an/a

-zł53m

Jun 30 2019n/an/a

-zł60m

Mar 31 2019n/an/a

-zł28m

Dec 31 2018zł476kzł476k

-zł23m

Sep 30 2018n/an/a

zł2m

Jun 30 2018n/an/a

zł14m

Mar 31 2018n/an/a

zł21m

Dec 31 2017zł655kzł655k

zł6m

Sep 30 2017n/an/a

zł13m

Jun 30 2017n/an/a

zł14m

Mar 31 2017n/an/a

zł10m

Dec 31 2016zł388kn/a

zł3m

Sep 30 2016n/an/a

zł493k

Jun 30 2016n/an/a

-zł528k

Mar 31 2016n/an/a

zł3m

Dec 31 2015zł426kn/a

zł6m

Compensation vs Market: Insufficient data to establish whether Pawel's total compensation is reasonable compared to companies of similar size in the Polish market.

Compensation vs Earnings: Pawel's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: RVU's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: RVU's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of RVU?
Owner TypeNumber of SharesOwnership Percentage
General Public4,482,15124.4%
Individual Insiders6,765,64036.9%
Institutions7,107,68338.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 75.45% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
27.19%
Pawel Przewiezlikowski
4,990,880PLN166.2m0%no data
9.65%
NN Investment Partners Holdings N.V.
1,771,000PLN59.0m0%0.04%
7.79%
Aviva Powszechne Towarzystwo Emerytalne Aviva Santander S.A.
1,430,521PLN47.6m0%0.27%
6.35%
Norges Bank Investment Management
1,165,503PLN38.8m0%no data
5.66%
Forum Towarzystwo Funduszy Inwestycyjnych S.A.
1,039,738PLN34.6m0%5.03%
5.04%
Boguslaw Sieczkowski
924,384PLN30.8m0%no data
2.97%
Allianz Asset Management AG
544,248PLN18.1m7.05%no data
1.8%
Piotr Romanowski
331,000PLN11.0m0%no data
1.52%
Skarbiec Towarzystwo Funduszy Inwestycyjnych S.A.
279,312PLN9.3m-9.45%0.49%
1.46%
Krzysztof Brzózka
267,321PLN8.9m0%no data
0.93%
AXA Towarzystwo Funduszy Inwestycyjnych S.A.
169,861PLN5.7m119.82%0.62%
0.78%
Esaliens TFI S.A.
142,929PLN4.8m0.78%0.47%
0.66%
Rafal Chwast
121,115PLN4.0m0%no data
0.51%
Tadeusz Wesolowski
92,975PLN3.1m0%no data
0.48%
Metlife Towarzystwo Funduszy Inwestycyjnych S.A.
88,918PLN3.0m-7.68%0.16%
0.45%
Santander Towarzystwo Funduszy Inwestycyjnych S.A.
82,328PLN2.7m-49.01%0.09%
0.43%
Generali Investments Towarzystwo Funduszy Inwestycyjnych S.A.
78,692PLN2.6m-22.58%0.31%
0.41%
Towarzystwo Funduszy Inwestycyjnych PZU SA
75,201PLN2.5m-0.66%0.09%
0.37%
Aviva Investors Poland Towarzystwo Funduszy Inwestycyjnych S.A.
67,022PLN2.2m-21.08%0.21%
0.33%
Millennium Towarzystwo Funduszy Inwestycyjnych SA
59,761PLN2.0m-15.35%0.43%
0.3%
Powszechne Towarzystwo Emerytalne PZU SA
54,454PLN1.8m-94.98%0.02%
0.11%
Thomas Turalski
20,100PLN669.3k0%no data
0.097%
Kamil Sitarz
17,865PLN594.9k0%no data
0.094%
BNPP Asset Management Holding
17,334PLN577.2k0%no data
0.087%
Quercus TFI S.A.
16,000PLN532.8k100%0.11%

Company Information

Ryvu Therapeutics S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Ryvu Therapeutics S.A.
  • Ticker: RVU
  • Exchange: WSE
  • Founded: 2007
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: zł611.237m
  • Shares outstanding: 18.36m
  • Website: https://www.ryvu.com

Number of Employees


Location

  • Ryvu Therapeutics S.A.
  • Leona Henryka Sternbacha 2
  • Kraków
  • 30-394
  • Poland


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RVUWSE (Warsaw Stock Exchange)YesCommon Bearer SharesPLPLNJul 2011
9Y4DB (Deutsche Boerse AG)YesCommon Bearer SharesDEEURJul 2011

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/03 00:00
End of Day Share Price2022/10/03 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.